Longport, Inc. Receives Purchase Orders and Signs Rental Agreements for EPISCAN I-200

Longport, Inc., (OTC BB: LPTI), a medical technology
specialist in high resolution ultrasound imaging, announced today that
it has received a purchase order for two EPISCAN I-200 ultrasound
scanners and has additionally entered into three separate rental
agreements.
   Maximum Medical, Inc. has ordered scanners to be placed at two
facilities that primarily serve a Native American population. These
facilities will be using the scanners in wound care and prevention
applications. At the same time, Longport has placed three units in the
UK under a rental agreement with an international aesthetic company to
assess the impact of an anti-aging process. Longport has also rented
another unit to a major manufacturer of medical lasers in the U.S. to
assess the impact of a laser-based aesthetic procedure. Finally, an
internationally recognized hospital in Switzerland is renting an
EPISCAN I-200 for use in a dermatology study.
   Paul Wilson, President of Longport, said, "We are very pleased to
have signed these agreements, which show sales originating from a
distributor as well as Longport's direct efforts. I congratulate
Maximum Medical on their success. These agreements also demonstrate
that our technology has applications in several diverse markets.
Moreover, the placement of units in both Europe and the U.S.
illustrates our international reach. We expect to announce further
sales and rentals in the near future."
   Tony Oglesby, President of Maximum Medical, said, "I am encouraged
by the reception and interest level at the facilities where our sales
team has introduced the EPISCAN I-200. We look forward to increasing
sales numbers, as practitioners see the ease and efficacy of the
technology."

   About Longport, Inc.

   Longport, Inc. of Glen Mills, Pennsylvania, is a medical
technology company that specializes in high resolution ultrasound
imaging. After several years and a multi-million dollar investment in
the technology, Longport has secured patents, copyrights, and FDA
permission to market. The Company's technology has been used to
engineer a unique high resolution ultrasound imaging system. For
further information please contact Longport, Inc. at 1-800-289-6863 or
visit our website at www.longportinc.com.

   Forward-looking Information and the Private Securities Litigation
Reform Act of 1995

   Certain statements in this press release, including statements
concerning product development milestones and anticipated events, are
"forward-looking statements" within the Private Litigation Reform Act
of 1995. Forward Looking Statements are based on the opinions and
estimates of management at the time the statements are made and are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those anticipated in the
forward-looking statements. The words "believe," "expect," "intend,"
"anticipate," variations of such words, and similar expressions
identify forward-looking statements, but their absence does not mean
that the statement is not forward-looking. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Factors
that could affect Longport's actual results include, among others,
uncertainties as to the Company's ability to manage potential
problems, delays or anticipated expenses, including problems, delays
or expenses involving manufacturing. Readers are cautioned not to
place undue reliance upon these forward-looking statements that speak
only to the date of this release. Reference is made to Longport's 2004
annual report on Form 10-K filed with the Securities and Exchange
Commission for a more definitive description of such factors.
Longport, Inc. undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date of this release or to reflect the
occurrence of unanticipated events.